Nyrada Reported Encouraging Preclinical Results In Cholesterol-Lowering Drug Study, Stock Zooms Up by 34%

  • Jul 06, 2020 AEST
  • Team Kalkine

Australian preclinical-stage drug discovery and development company, Nyrada Inc. (ASX: NYR), in its cholesterol-lowering drug development program to treat hypercholesterolemia, made a big step forward towards replacing expensive current injections with the first-ever oral pill. 

Nyrada’s Cholesterol-lowering study indicates that in healthy human white blood cells, NYR’s PCSK9 inhibitor (NYX-PCSK9i) demonstrates equivalency to the two FDA approved, marketed monoclonal PCSK9 antibody drugs, Repatha® and Praluent®, the combined FY2019 sales of which was over US$900 million. 

Significantly, the results were confirmed both with and without the presence of a statin (Mevastatin), unlocking the potential to develop combined PCSK9-statin single-pill treatment for high LDL cholesterol.  

 


Disclaimer
The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. All pictures are copyright to their respective owner(s). Kalkinemedia.com does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.

 

Which stock gained the most attention in 2019? Find out in our exclusive report on the much talked about lithium stocks which gained the most investor attention amidst the volatile and high drama electric vehicle market.

Read about the shift in the Electric Vehicle market in 2020 and the consequent focus on Lithium in our report.

Get an insight into the lithium prices and the trends. The supply glut kept the lithium prices in check. The escalated bilateral trade dispute between the United States and China significantly impacted the lithium chemical prices.

Understand the performance of mining companies. The lithium mining companies managed to sail through the turbulent white gold market by limiting the production in correspondence with the demand from the offtake partners.

CLICK HERE FOR YOUR FREE REPORT!
   
x
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK